31 unknown. 31 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Unknown 31 |
| Phase 1 | 7 | Unknown 7 |
| Phase 3 | 2 | Unknown 2 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib Sunitinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Unknown | Instituto do Cancer do Estado de São Paulo | 7 | 2017-12-11 | 2019-09-04 |
| Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Sunitinib - Type B3 Thymoma, Thymic Carcinoma | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 56 | 2017-03-02 | 2021-06-09 |
| Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial Sunitinib, Isoquercetin, Placebo - Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | Unknown | Consorzio Oncotech | 104 | 2016-11-01 | 2017-01-18 |
| Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients Dose-dense doxorubicin/cyclophosphamide + sunitinib, Dose-dense doxorubicin/cyclophosphamide - Breast Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 98 | 2016-05-01 | 2016-06-06 |
| Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma Sunitinib - Kidney Neoplasms, Metastatic Renal Cell Cancer | Phase 2 | Unknown | Centre Hospitalier Universitaire de Besancon | 226 | 2016-02-19 | 2021-11-29 |
| Multiple Treatments for Ebola Virus Disease (EVD) Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan - Ebola Virus Disease | Phase 1 / Phase 2 | Unknown | Clinical Research Management, Inc. | 150 | 2015-04-01 | 2015-03-05 |
| A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. Sunitinib - Metastatic Renal Cell Carcinoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 80 | 2015-03-01 | 2016-03-01 |
| Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) Sunitinib, Bevacizumab - Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | King Faisal Specialist Hospital & Research Center | 77 | 2014-12-01 | 2018-08-10 |
| Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） Anlotinib, Sunitinib maleate - Anlotinib, RCC | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 133 | 2013-12-01 | 2016-04-26 |
| Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Docetaxel, Sunitinib - Solid Tumors, Breast Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 80 | 2013-05-01 | 2016-06-22 |
| Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen Sunitinib, chemotherapy - Cancer, Lung Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 50 | 2013-03-01 | 2013-05-09 |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Lanreotide, Placebo (for sunitinib), Sunitinib - Carcinoid Tumors | Phase 2 | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 44 | 2013-01-07 | 2017-01-31 |
| Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma Sunitinib, Temozolomide, Radiation Therapy - Glioblastoma Multiforme | Phase 2 | Unknown | Bassam Abdulkarim | 45 | 2012-08-01 | 2016-10-10 |
| Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer malate Given orally - Non-small Cell Lung Cancer | Phase 2 | Unknown | Third Military Medical University | 30 | 2010-09-01 | 2010-09-28 |
| Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor Arm A, Arm B - Breast Cancer | Phase 2 | Unknown | National University Hospital, Singapore | 73 | 2010-08-01 | 2016-06-22 |
| Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Sunitinib - Clear Cell Renal Cell Carcinoma, Metastasis | Phase 2 | Unknown | Korean Urological Oncology Society | 32 | 2009-07-01 | 2011-06-23 |
| Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib Autologous renal cell vaccine based on DNP modified cells - Renal Cell Cancer | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 13 | 2009-06-01 | 2009-04-29 |
| Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer exemestane, sunitinib malate, placebo - Breast Cancer | Phase 1 / Phase 2 | Unknown | Institut Català d'Oncologia | 70 | 2009-03-01 | 2013-08-12 |
Showing 20 of 31. Sign in to see all of them.
Carcinoma, Renal Cell (10) · Neoplasm Metastasis (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Kidney Neoplasms (4) · Glioblastoma (3) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Brain Neoplasms (1) · Carcinoid Tumor (1) · Colorectal Neoplasms (1) · Fatigue (1) · Hemorrhagic Fever, Ebola (1) · Lung Neoplasms (1) · Neoplasms (1)
National University Hospital, Singapore (3) · Amsterdam UMC, location VUmc (2) · Abramson Cancer Center at Penn Medicine (1) · Alberta Health services (1) · Asan Medical Center (1) · Australasian Sarcoma Study Group (1) · Bassam Abdulkarim (1) · Campania Younger Oncologists Association (1) · Centre Hospitalier Universitaire de Besancon (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese Academy of Medical Sciences (1) · Clinical Research Management, Inc. (1) · Consorzio Oncotech (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1)
China (4) · Italy (3) · Singapore (3) · Austria (2) · Canada (2) · France (2) · Netherlands (2) · South Korea (2) · Spain (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Germany (1) · Saudi Arabia (1)
Bernhard Eigl, M.D. (1) · Cheng-Jeng Tai, M.D. (1) · Christopher Woods, MD, MPH (1) · David L Hoover, MD (1) · David Thomas, MB BS PhD (1) · Edward F. McClay, MD (1) · Giuseppe Di Lorenzo, MD (1) · Guenther Stockhammer, MD, Prof. (1) · Henk Verheul, Prof. M.D. (1) · Hovav Nechushtan, MD PHD (1) · Jae-Lyun Lee, MD, PhD (1) · Joaquim Bellmunt, MD, PhD (1) · John M Griffiss, MD (1) · Jun Guo, MD,PHD (1)
PMID 12712448, PMID 15201427, PMID 15725919, PMID 17570676, PMID 19461405, PMID 21277078, PMID 22045104, PMID 22228449, PMID 23747347, PMID 24311637, PMID 25411417, PMID 26768569, PMID 29650037, PMID 33203399, PMID 34928481, PMID 35699834, PMID 36749752, PMID 39384801, PMID 40973474
2015 (1), 2016 (1)